Alzheimer’s disease (AD) is a common cause of dementia among elderly people. Hyperphosphorylation and aggregation of tau correlates with the clinical progression of AD; therefore, therapies targeting the aggregation of tau may have potential applications for anti-AD drug development. Several inhibitors of tau aggregation, including small molecules and antibodies, have been found to decrease the aggregation of tau and the corresponding pathology.
Objective:
To screen one kind of single-chain variable fragment (scFv) antibody which could inhibit the aggregation of tau and ameliorate its cytotoxicity.
Methods/Results:
Using phosphorylated tau (pTau) as an antigen, we obtained a scFv antibody via the screening of a high-capacity phage antibody library. Biochemical analysis revealed that this scFv antibody (scFv T1) had a strong ability to inhibit pTau aggregation both in dilute solutions and under conditions of macromolecular crowding. ScFv T1 could also depolymerize preformed pTau aggregates in vitro. Furthermore, scFv T1 was found to be able to inhibit the cytotoxicity of extracellular pTau aggregates and ameliorate tau-mediated toxicity when coexpressed with a hTauR406W mutant in the eye of transgenic Drosophila flies.
Conclusion:
This scFv T1 antibody may be a potential new therapeutic agent against AD. Our methods can be used to develop novel strategies against protein aggregation for the treatment of neurodegenerative diseases.
PanzaF, SolfrizziV, FrisardiV, ImbimboBP, CapursoC, D’IntronoA, ColaciccoAM, SeripaD, VendemialeG, CapursoA, PilottoA (2009) Beyond the neurotransmitter-focused approach in treating Alzheimer’s disease: Drugs targeting beta-amyloid tau protein. Aging Clin Exp Res21, 386–406.
4.
BroncelM, KrauseE, SchwarzerD, HackenbergerCP (2012) The Alzheimer’s disease related tau protein as a new target for chemical protein engineering. Chem Eur J18, 2488–2492.
5.
KimuraT, FukudaT, SaharaN, YamashitaS, MurayamaM, MizorokiT, YoshiikeY, LeeB, SotiropoulosI, MaedaS, TakashimaA (2010) Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem285, 38692–38699.
6.
ZilkaN, KontsekovaE, NovakM (2008) Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimer Dis15, 169–179
WischikCM, EdwardsPC, LaiRY, RothM, HarringtonCR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A93, 11213–11218.
9.
TaniguchiS, SuzukiN, MasudaM, HisanagaS, IwatsuboT, GoedertM, HasegawaM (2005) Inhibition of heparin-induced tau filament formation by phenothiazines polyphenols porphyrins. J Biol Chem280, 7614–7623.
10.
PickhardtM, GazovaZ, von BergenM, KhlistunovaI, WangY, HascherA, MandelkowEM, BiernatJ, MandelkowE (2005) Anthraquinones inhibit tau aggregation dissolve Alzheimer’s paired helical filaments in vitro in cells. J Biol Chem280, 3628–3635.
11.
PickhardtM, LarbigG, KhlistunovaI, CoksezenA, MeyerB, MandelkowEM, SchmidtB, MandelkowE (2007) Phenylthiazolyl-hydrazide its derivatives are potent inhibitors of tau aggregation toxicity in vitro in cells. Biochemistry46, 10016–10023.
12.
BlairLJ, ZhangB, DickeyCA (2013) Potential synergy between tau aggregation inhibitors tau chaperone modulators. Alzheimer Res Ther5, 41.
13.
TaniguchiT, SumidaM, HiraokaS, TomooK, KakehiT, MinouraK, SugiyamaS, InakaK, IshidaT, SaitoN, TanakaC (2005) Effects of different anti-tau antibodies on taufibrillogenesis: RTA-1 RTA-2 counteract tau aggregation. FEBS Lett579, 1399–1404.
14.
Esteves-VillanuevaJO, TrzeciakiewiczH, LoefflerDA, MartićS (2015) Effects of tau domain-specific antibodies intravenous immunoglobulin on tau aggregation aggregate degradation. Biochemistry54, 293–302.
BoutajangoutA, IngadottirJ, DaviesP, SigurdssonEM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline clears tau aggregates from the brain. J Neurochem118, 658–667.
17.
PanzaF, FrisardiV, SolfrizziV, ImbimboBP, LogroscinoG, SantamatoA, GrecoA, SeripaD, PilottoA (2012) Immunotherapy for Alzheimer’s disease: From anti-β-amyloid to tau-based immunization strategies. Immunotherapy4, 213–238.
DuL, ZhouLJ, PanXJ, WangYX, XuQZ, YangZH, WangY, LiuXD, ZhuMX, ZhouPK (2010) Radiosensitization growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcsin vitroin vivo.. Radiat Oncol5, 70–80.
20.
CohlbergJA, LiJ, UverskyVN, FinkAL (2002) Heparin other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.. Biochemistry41, 1502–1511.
AlonsoAC, ZaidiT, Grundke-IqbalI, IqbalK (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA91, 5562–5566.
23.
BrandAH, PerrimonN (1993) Targeted gene expression as a means of altering cell fates generating dominant phenotypes. Development118, 401–415.
MaQ, FanJB, ZhouZ, ZhouBR, MengSR, HuJY, ChenJ, LiangY (2012) The contrasting effect of macromolecular crowding on amyloid fibril formation. PLoS One7, e36288.
26.
FriedhoffP, von BergenM, MandelkowEM, DaviesP, MandelkowE (1998) A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci USA95, 15712–15717.
27.
MeyerV, DinkelPD, HagerER, MargittaiM (2014) Amplification of tau fibrils from minute quantities of seeds. Biochemistry53, 5804–5809.
28.
MirbahaH, HolmesBB, SandersDW, BieschkeJ, DiamondMI (2015) Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem290, 14893–14903.
FáM, PuzzoD, PiacentiniR, StaniszewskiA, ZhangH, BaltronsMA, Li PumaDD, ChatterjeeI, LiJ, SaeedF, BermanHL, RipoliC, GulisanoW, GonzalezJ, TianH, CostaJA, LopezP, DavidowitzE, YuWH, HaroutunianV, BrownLM, PalmeriA, SigurdssonEM, DuffKE, TeichAF, HonigLS, SierksM, MoeJG, D’AdamioL, GrassiC, KanaanNM, FraserPE, ArancioO (2016) Extracellular tau oligomers produce an immediate impairment of LTP memory. Sci Rep20, 19393.
31.
Sebastián-SerranoÁ, de Diego-GarcíaL, Díaz-HernándezM (2018) The neurotoxic role of extracellular tau protein. Int J Mol Sci19, 998.
32.
MedinaM, AvilaJ (2015) Further understanding of tau phosphorylation: Implications for therapy. Expert Rev Neurother15, 115–122.
33.
WardSM, HimmelsteinDS, LanciaJK, FuYF, PattersonKR, BinderLI (2013) TOC1: Characterization of a selective oligomeric tau antibody. J Alzheimer Dis37, 593–602.
34.
UsenovicM, NiroomS, DroletRE, YaoL, GasparRC, HatcherNG, SchachterJ, RengerJJ, Parmentier-BatteurS (2015) Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J Neurosci35, 14234–14250.
35.
de CalignonA, PolydoroM, Suarez-CalvetM, WilliamC, AdamowiczDH, KopeikinaKJ, PitstickR, SaharaN, AsheKH, CarlsonGA, Spires-JonesTL, HymanBT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron73, 685–697.
36.
EllisRJ (2001) Macromolecular crowding: An important but neglected aspect of the intracellular environment. Curr Opin Struct Biol11, 114–119.
37.
MintonAP (2006) How can biochemical reactions within cells differ from those in test tubes?J Cell Sci119, 2863–2869.
38.
ZhouZ, FanJB, ZhuHL, ShewmakerF, YanX, ChenX, ChenJ, XiaoGF, GuoL, LiangY (2009) Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J Biol Chem284, 30148–30158.
TianH, DavidowitzE, LopezP, EmadiS, MoeJ, SierksM (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol2013, 260787.
YamadaK (2017) Extracellular tau and its potential role in the propagation of tau pathology. Front Neurosci29, 00667.
43.
ReedLA, GrabowskiTJ, SchmidtML, MorrisJC, GoateA, SolodkinA, Van HoesenGW, SchelperRL, TalbotCJ, WraggMA, TrojanowskiJQ (1997) Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol42, 564–572.
44.
NishimuraI, YangYF, LuBW (2004) PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell116, 671–682.
45.
ChaiX, WuS, MurrayTK, KinleyR, CellaCV, Sims BucknerN, HanmerJ, DaviesP, O’NeillMJ, HuttonML, CitronM (2011) Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of tau pathology delay of disease progression. J Biol Chem286, 34457–34467.
46.
d’AbramoC, AckerCM, JimenezHT, DaviesP (2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity.. PLoS One8, e62402.
47.
UmedaT, EguchiH, KunoriY, MatsumotoY, TaniguchiT, MoriH, TomiyamaT (2015) Passive immunotherapy of tauopathy targeting pSer413-tau: A pilot study in mice. Ann Clin Transl Neurol2, 241–255.
LynchSM, ZhouC, MesserA (2008) An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation toxicity. J Mol Biol77., 136–147.
50.
YueS, LiY, WangXH, BaiH, XiaJ, JiangL, JiY, FanL, HeZ, ChenQ (2008) The toxicity of β-amyloid is attenuated by interaction with its specific human scFv E3 in vitro. Life Sci82, 1249–1255.
51.
RyanDA, MastrangeloMA, NarrowWC, SullivanMA, FederoffHJ, BowersWJ (2010) Aβ-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior pathology in Alzheimer’s disease mice. Mol Ther18, 1471–1481.
52.
IsingC, GallardoG, LeynsCEG, WongCH, JiangH, StewartF, KoscalLJ, RohJ, RobinsonGO, SerranoJR, HoltzmanDM (2017) AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med214, 1227–1238.
53.
VitaleF, GilibertoL, RuizS, SteslowK, MarambaudP, d’AbramoC (2018) Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun6, 82.
54.
SpencerB, BrüschweilerS, Sealey-CardonaM, RockensteinE, AdameA, FlorioJ, ManteM, TrinhI, RissmanRA, KonratR, MasliahE (2018) Selective targeting of 3 repeat tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol136, 69–87.
